| アブストラクト | INTRODUCTION: In November 2018, the European Medicines Agency (EMA) restricted the use of fluoroquinolones (used by mouth, injections or inhalation) in the context of a referral due to long-lasting and potentially irreversible adverse drug reactions (ADRs). Fluoroquinolones should no longer be used to treat mild or moderate bacterial infections unless other antibacterials cannot be used. OBJECTIVES: The first aim of our study was to analyze whether in the period before compared with after the referral the characteristics of spontaneous ADR reports related to fluoroquinolones differed and whether specific ADRs were more frequently reported for fluoroquinolones compared with cotrimoxazole. Secondly, we analyzed whether the ADR profile differed between individual fluoroquinolones. Finally, the number of fluoroquinolone reports was considered in relation to the number of outpatient drug prescriptions. METHODS: All spontaneous ADR reports from Germany received before the referral (01/2014-12/2019) and after the referral (01/2020-12/2022) for adults in which fluoroquinolones (n = 2575; n = 967) or cotrimoxazole (n = 299, n = 275) were reported as suspected/interacting were identified in the European ADR database, EudraVigilance. The ADR reports were descriptively analyzed concerning the reported characteristics. Odds ratios (ORs) and their 95% confidence intervals (CIs) were estimated by logistic regression analyses, which were performed to investigate whether aortic aneurysms, retinal detachments, cardiac arrhythmias, peripheral polyneuropathies, nervous system disorders, toxic liver diseases and non-traumatic injuries of muscles, tendons and synovialis were more frequently reported for fluoroquinolones compared with cotrimoxazole. Stratified analyses between fluoroquinolones were conducted by calculating ORs and their 95% CIs by using two-by-two tables. Reporting rates were calculated by dividing the number of fluoroquinolone reports by the number of fluoroquinolone prescriptions. RESULTS: Reporting rates of fluoroquinolones clearly increased until 2019 and decreased afterward. Only minor differences in the characteristics of fluoroquinolone reports (e.g., regarding the indications) were observed in reports received before and after the referral. In both periods, peripheral neuropathies, nervous system, and muscle and tendon disorders were more often reported for fluoroquinolones than cotrimoxazole. In the pooled fluoroquinolone-stratified analyses, (i) peripheral neuropathies and nervous system disorders were more frequently reported for ciprofloxacin, (ii) non-traumatic injuries of muscle, tendon, and synovialis were more often reported for levofloxacin, and (iii) cardiac arrhythmias and toxic liver diseases were more frequently reported for moxifloxacin compared with the other fluoroquinolones. CONCLUSION: In accordance with a reminder sent by the EMA referring to prescribing trends for fluoroquinolones, our study showed that the characteristics of spontaneous ADR reports for fluoroquinolones after the referral were similar to those before the referral, underlining the importance of adhering to the recommended restrictions issued by the EMA. In addition, we observed individual differences between ciprofloxacin, levofloxacin, and moxifloxacin with regard to their ADR profile. Further studies are needed to confirm our results. |
|---|
| 投稿者 | Dubrall, Diana; Wicherski, Julia; Below, Maike; Gortzen-Patin, Jan; Schmid, Matthias; Zenker, Sven; Haenisch, Britta; Sachs, Bernhardt |
|---|
| 組織名 | Institute for Medical Biometry, Informatics and Epidemiology, University Hospital;Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. Diana.Dubrall@bfarm.de.;Research Division, Federal Institute of Drugs and Medical Devices (BfArM),;Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Germany. Diana.Dubrall@bfarm.de.;Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Germany.;Central Research Institute for Ambulatory Health Care in Germany, Salzufer 8,;10587, Berlin, Germany.;Department of Anesthesiology and Intensive Care Medicine, University Hospital;Bonn, Venusberg-campus 1, 53127, Bonn, Germany.;Staff Unit for Medical and Scientific Technology Development and Coordination;(MWTek), University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.;Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.;German Center for Neurodegenerative Diseases (DZNE) e. V., Venusberg-Campus 1/99,;53127, Bonn, Germany.;Germany Center for Translational Medicine, University Hospital Bonn,;Venusberg-Campus 1, 53127, Bonn, Germany.;Department for Dermatology and Allergy, University Hospital RWTH Aachen,;Morillenhang 27, 52074, Aachen, Germany. |
|---|
